Cytological examination of cerebrospinal fluid

Česká verzia

Authors: Jaroslava Dušková ^1,2; Ondřej Sobek ²
Authors place of work: Ústav patologie 1. LF UK a VFN ¹; Laboratoř pro likvorologii, neuroimunologii, patologii a speciální diagnostiku, Topelex s. r. o., Praha ²
Published in the journal: Čes.-slov. Patol., 55, 2019, No. 3, p. 145-157
Category: Přehledový článek

Summary

Cytological examination of cerebrospinal fluid (CSF) has some specifics. In the pre-analytical phase, due to collection into a tube without fixation and hypooncotic nature with rapid cell degradation, processing is required within 2-3 hours. In the subsequent analytical phase it is necessary to take into account the quantitative limit of the sample due to regular parallel cytological processing and non-morphological methods. A regular entry step of cytological examination is the quantification of cellularity. Even oligocellular samples may exhibit severe cytological findings.

In the category of inflammatory processes, the cytological diagnosis of purulent meningitis within a few hours has a fundamental influence on prognosis of the disease. Non-purulent inflammations with a broad differential diagnosis are specified not only by cytological images, but also by parallel non-morphological examinations aimed at detecting an infectious agent or autoimmune nature of inflammation.

Neoplastic processes in the intermeningeal space generally require immunocytochemical verification. The minimum amount of CSF for immunocytochemical examinations is 3-5 ml. The requirement for these examinations resulting from the baseline assessment may indicate the need for another sample.

If the appropriate procedures and interpretations are followed in the context of parallel non-morphological examinations, the cytological examination of MM can contribute significantly to the diagnosis of pathological conditions in CSF spaces.

Keywords:

Multiple sclerosis – Meningitis – cytology of the cerebrospinal fluid – intracranial bleeding – meningeal carcinosis

Zdroje

1. Sakka L, Coll G, Chazal J. Anatomy and physiology of cerebrospinal fluid. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128(6): 309-316.

2. Hajdu SI. A note from history: Discovery of the cerebrospinal fluid. Ann Clin Lab Sci 2003; 33(3): 334-336.

3. Wynter W. Four cases of tubercular meningitis in which paracentesis of the theca vertebralis was performed for the relief of fluid pressure. Lancet 1891; 137(3531): 981-982.

4. Quincke H. Die Lumbalpunction des Hydrocephalus. Berl klin Wochenschr 1891; 28(929-933; 965-968.

5. Merritt HH, Fremont-Smith F. The cerebrospinal fluid ed.). Philadelphia, London,: W. B. Saunders Company; 1937:

6. Herndon RM, Brumback RA. The cerebrospinal fluid ed.). Boston: Kluwer Academic Publishers; 1989:

7. Taussig L. Liquor cerebrospinalis: Lumbální punkce v diagnostice, prognostice a terapii. Praha: Mladá Generace Lékařů; 1926: 440.

8. Goedert M. Oskar Fischer and the study of dementia. Brain 2009; 132(Pt 4): 1102-1111.

9. Abbott NJ, Pizzo ME, Preston JE, Janigro D, Thorne RG. The role of brain barriers in fluid movement in the cns: Is there a ‘glymphatic’ system? Acta Neuropathol 2018; 135(3): 387-407.

10. Kelbich P, Hejčl A, Selke Krulichová I, Et Al. Coefficient of energy balance, a new parameter for basic investigation of the cerebrospinal fluid. Clin Chem Lab Med 2014; 52(7): 1009-1017.

11. Kybicová K, Lukavská A, Balátová P. Lymeská borrelióza – kultivace Borrelia burgdorferi sensu lato. Zprávy CEM (SZÚ, Praha) 2018; 27(5): 113-115.

12. Duskova J, Sobek O. Assisting the neurologist in diagnosis of cns malignancies - current possibilities and limits of cerebrospinal fluid cytology and immunocytochemistry. Brain Behav 2017; 7(10): e 00805 https://doi.org/00810.01002/brb00803.00805.

13. Chivukula M, Dabbs DJ. Immunocytology. In: Dabbs DJ, eds. Diagnostic immunohistochemistry. Theranostic and genomic applications ed). Philadelphia: Saunders - Elsevier; 2010: 901-922.

14. Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic tools for neoplastic meningitis: Detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 2009; 36(4 Suppl 2): S35-45.

15. Chandra A, Cross P, Denton K, et al. The BSCC code of practice--exfoliative cytopathology (excluding gynaecological cytopathology). Cytopathology 2009; 20(4): 211-223.

16. Weston CL, Glantz MJ, Connor JR. Detection of cancer cells in the cerebrospinal fluid: Current methods and future directions. Fluids Barriers CNS 2011; 8(1): 14.

17. Zhao H, Ma M, Zhang L, et al. Diagnosis of central nervous system lymphoma via cerebrospinal fluid cytology: A case report. BMC Neurol 2019; 19(1): 90.

18. De May RM. The art and science of cytopathology (1st ed.). Chicago: ASCP Press; 1995: 427-462.

19. Spieler P, Rössle M. Nongynecologic cytopathology (1st ed.). Berlin- Heidelberg: Springer; 2012: 491-513.

20. Sobek O, Adam P, Koudelková M, Štourač P, Mareš J. Algoritmus vyšetření likvoru v návaznosti na doporučení sekce neuroimunologie a likvorologie české neurologické společnosti jep. Cesk Slov Neurol N 2012; 75/108 (2): 159-163.

21. Reiber H. Flow rate of cerebrospinal fluid (csf)- a concept common to normal blood-csf barrier function and to dysfunction in neurological diseases. J Neurol Sci 1994; 122: 189-203.

22. Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology. Definition, criteria, and explanatory notes. (2nd ed.). Springer; 2018: 236.

23. Nayar R, Wilbur DC. The Bethesda system for reporting cervical cytology (3rd ed.). Cham, Heidelberg, New York, Dordrecht, London: Springer; 2015:

24. Pitman MB, Leyfield LJ. The Papanicolaou society of cytopathology system for reporting pancreaticobiliary cytology (1st ed.). Cham Heidelberg, New York, London: Springer; 2015:

25. Rosenthal DL, Wojcik EM, Kurtycz DFI. The Paris system for reporting urinary cytology (1st ed.). Cham, Heidelberg, New York, Dordrecht, London: Springer 2016:

26. Faquin WC, Rossi ED. The Milan system for reporting salivary gland cytopathology (1st ed.). New York, NY: Springer 2018: